Zong Jianing, Li Yun, Zhou Wanqi, Mao Mengfei, Xu Xin, Cai Simin, Li Meixia, Ding Kan
Glycochemistry and Glycobiology Lab, Carbohydrate Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, Jiangsu Province 210029, China.
Glycochemistry and Glycobiology Lab, Carbohydrate Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
Int J Biol Macromol. 2025 Jan;284(Pt 1):137936. doi: 10.1016/j.ijbiomac.2024.137936. Epub 2024 Nov 22.
Buddleja officinalis has been used as a traditional Chinese medicine for years. Although evidence has demonstrated it can enhance liver function, the active material basis remains unknown. We hypothesize polysaccharides from Buddleja officinalis may be the active material against liver disease. Herein, we elucidated the structure of a novel pectin-like polysaccharide designed BOM0.05S2 with a molecular weight of 13.6 kDa. Combined with endo-1, 4-β-Mannanase degradation, we found its backbone consists of alternate 1, 2, 4-linked α-Rhap and 1, 4-linked α-GalpA (RG-I type pectin) and mannoglucan, with branches of 1, 4-, 1, 6- and 1, 3, 6-linked β-Galp, T-, 1, 5- and 1, 3, 5-linked α-Araf, T-linked β-Manp and T-linked α-Glcp substituted at C-4 of 1, 2, 4-linked α-Rhap and C-6 of 1, 4, 6-linked α-Glcp. As speculated, BOM0.05S2 showed a significant improvement on carbon tetrachloride (CCl)-induced liver damage in mice. Bioactivity test showed that BOM0.05S2 reduced AST, ALT and four indexes of liver fibrosis including LN, HA, IV-C, PC-III. Further, we demonstrated that BOM0.05S2 attenuated the collagenous fiber and α-SMA in liver. These findings highlight the potential of BOM0.05S2 as a lead compound for the treatment of liver fibrosis.
多年来，密蒙花一直被用作传统中药。尽管有证据表明它可以增强肝功能，但其活性物质基础仍然未知。我们推测密蒙花中的多糖可能是抗肝病的活性物质。在此，我们阐明了一种新型果胶样多糖BOM0.05S2的结构，其分子量为13.6 kDa。结合内切-1,4-β-甘露聚糖酶降解，我们发现其主链由交替的1,2,4-连接的α-Rhap和1,4-连接的α-GalpA（RG-I型果胶）以及甘露葡聚糖组成，在1,2,4-连接的α-Rhap的C-4和1,4,6-连接的α-Glcp的C-6处有1,4-、1,6-和1,3,6-连接的β-Galp、T-、1,5-和1,3,5-连接的α-Araf、T-连接的β-Manp和T-连接的α-Glcp分支取代。正如推测的那样，BOM0.05S2对四氯化碳（CCl）诱导的小鼠肝损伤有显著改善作用。生物活性测试表明，BOM0.05S2降低了AST、ALT以及包括LN、HA、IV-C、PC-III在内的四项肝纤维化指标。此外，我们证明BOM0.05S2减轻了肝脏中的胶原纤维和α-SMA。这些发现突出了BOM0.05S2作为治疗肝纤维化先导化合物的潜力。
